Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on October 31st, 2022%
(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)
31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger
By Alan, on October 29th, 2022%
Most Americans believe the U.S. should be the world leader in scientific achievement, and support continued U.S. government investments in science. . . . → Read More: Infographic – US Public Supports Govt Science Spending
By Alan, on October 28th, 2022%
A genomic analytics company says an ethnicity algorithm added to a personal health questionnaire improves risk assessments for breast cancer across all populations. . . . → Read More: AI Analytics Boost Breast Cancer Assessment Diversity
By Alan, on October 27th, 2022%
Research with lab animals shows an experimental cancer vaccine generates immune-system cells that infiltrate solid tumors and reduce the tumor’s protective environment. . . . → Read More: Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors
By Alan, on October 26th, 2022%
Results from a clinical trial show an experimental one-time antibody therapy, even at low doses, lowers levels of HIV virus in people living with the disease. . . . → Read More: Trial Shows Antibody Neutralizes, Reduces HIV Virus
By Alan, on October 25th, 2022%
A new biotechnology company is creating cancer immunotherapies that it says harness more of the full power of T-cells in the immune system to attack tumors. . . . → Read More: Immunotherapy Start-Up Launches Collaboration, Raises $65M
By Alan, on October 24th, 2022%
A California state research agency is funding preclinical development of a gel designed to regenerate stem cells in the skin to help heal venous skin ulcers. . . . → Read More: Grant Funds Regenerative Gel for Treating Skin Ulcers
By Alan, on October 22nd, 2022%
Venture funding for start-ups worldwide applying digital technologies to health care continued to fall in the third quarter of 2022, both in deals and dollars invested. . . . → Read More: Infographic – Q3 Digital Health Venture Funds Slide
By Alan, on October 21st, 2022%
A developer of faster infection diagnostics is receiving another $8.2 million from an international group supporting solutions to antibiotic resistant microbes. . . . → Read More: New Funds Awarded for Rapid Infection Diagnostics
By Alan, on October 20th, 2022%
A clinical trial is underway testing a synthetic antibody designed to prevent SARS-CoV-2 viral infections in people with compromised immune systems. . . . → Read More: Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
You must be logged in to post a comment.